Hypoxia-mediated induction of the polyamine system provides opportunities for tumor growth inhibition by combined targeting of vascular endothelial growth factor and ornithine decarboxylase.
Hypoxia is a hallmark of solid tumors, which may offer opportunities for targeted therapies of cancer; however, the mechanisms that link hypoxia to malignant transformation and tumor progression are not fully understood. Here, we show that up-regulation of the polyamine system promotes cancer cell survival during hypoxic stress. Hypoxia was found to induce polyamine transport and the key enzyme of polyamine biosynthesis, ornithine decarboxylase (ODC), in a variety of cancer cell lines. Increased ODC protein expression was shown in hypoxic, GLUT-1-expressing regions of tumor spheroids and experimental tumors, as well as in clinical tumor specimens. Hypoxic induction of the polyamine system was dependent on antizyme inhibitor (i.e., a key positive regulator of ODC and polyamine transport), as shown by RNA interference experiments. Interestingly, depletion of the polyamines during hypoxia resulted in increased apoptosis, which indicates an essential role of the polyamines in cancer cell adaptation to hypoxic stress. These results were supported by experiments in an in vivo glioma tumor model, showing significantly enhanced antitumor effects of the antiangiogenic, humanized anti-vascular endothelial growth factor (VEGF) antibody bevacizumab when used in combination with the well-established, irreversible inhibitor of ODC, alpha-difluoromethylornithine. Our results provide important insights into the hypoxic stress response in malignant cells and implicate combined targeting of VEGF and ODC as an alternative strategy to treat cancer disease.
Svensson
Katrin J
KJ
Division of Oncology, Department of Clinical Sciences, Lund University Hospital, Sweden.
Welch
Johanna E
JE
Kucharzewska
Paulina
P
Bengtson
Per
P
Bjurberg
Maria
M
Påhlman
Sven
S
Ten Dam
Gerdy B
GB
Persson
Lo
L
Belting
Mattias
M
D020533:Angiogenesis Inhibitors / Q000008:administration & dosage*; D000818:Animals; D000911:Antibodies, Monoclonal / Q000008:administration & dosage*; D061067:Antibodies, Monoclonal, Humanized; D000068258:Bevacizumab; D015317:Biogenic Polyamines / Q000502:physiology*; D002352:Carrier Proteins / Q000502:physiology; D015687:Cell Hypoxia; D002478:Cells, Cultured; D004359:Drug Therapy, Combination; D000518:Eflornithine / Q000008:administration & dosage* / Q000494:pharmacology; D005260:Female; D051272:Glucose Transporter Type 1 / Q000032:analysis; D006801:Humans; D051379:Mice; D016513:Mice, SCID; D009369:Neoplasms / Q000188:drug therapy*; D009955:Ornithine Decarboxylase / Q000378:metabolism; D065108:Ornithine Decarboxylase Inhibitors; D013096:Spermine / Q000493:pharmacokinetics; D042461:Vascular Endothelial Growth Factor A / Q000037:antagonists & inhibitors*
C484011:AZIN1 protein, human; D020533:Angiogenesis Inhibitors; D000911:Antibodies, Monoclonal; D061067:Antibodies, Monoclonal, Humanized; D015317:Biogenic Polyamines; D002352:Carrier Proteins; D051272:Glucose Transporter Type 1; D065108:Ornithine Decarboxylase Inhibitors; D042461:Vascular Endothelial Growth Factor A; D013096:Spermine; D000068258:Bevacizumab; D009955:Ornithine Decarboxylase; D000518:Eflornithine